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Abstract
Background: Many effective treatments for nicotine addiction inhibit noradrenaline reuptake. Three recent studies
have suggested that another noradrenaline reuptake inhibitor, atomoxetine, may reduce smoking behaviors.
Methods: The present double-blind, placebo-controlled, fixed-dose study was carried out over 21 days during
which administration of 40 mg atomoxetine was compared to placebo in 17 individuals. Of these, nine were
randomized to atomoxetine and eight to placebo. Baseline and weekly measurements were made using the
Cigarette Dependence Scale (CDS), Cigarette Withdrawal Scale (CWS), Questionnaire of Smoking Urges (QSU),
reported number of cigarettes smoked, and salivary cotinine levels.
Results: The study results showed that all those on placebo completed the study. In marked contrast, of the nine
individuals who started on atomoxetine, five dropped out due to side effects. In a completer analysis there were
statistically significant differences at 14 and 21 days in several measures between the atomoxetine and placebo
groups, including CDS, CWS, QSU, number of cigarettes smoked (decreasing to less than two per day in the
treatment group who completed the study), and a trend towards lower mean salivary cotinine levels. However,
these differences were not seen in a last observation carried forward (LOCF) analysis.
Conclusions: In summary, this is the first study to examine the use of atomoxetine in non-psychiatric adult
smokers for a period of more than 7 days, and the findings suggest that atomoxetine might be a useful treatment
for nicotine addiction. However, the dose used in the current study was too high to be tolerated by many adults,
and a dose-finding study is required to determine the most appropriate dose for future studies of this potential
treatment for smoking cessation.
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Introduction
Smoking is recognized as a global concern. Nicotine
addiction affects not only tobacco users, but also their
families and society in general. Impacting both mental
and physical health, smoking addiction generates high
costs associated with multidimensional measures, signifi-
cantly affecting economy of countries worldwide [1]. It
has been predicted that annual worldwide smoking-
related deaths will reach roughly 3 million people per
year in industrialized countries and 7 million per year in
developing countries by 2030 [2].
For several decades researchers have been attempting
to find effective therapies for smoking cessation. Several
studies have demonstrated that alterations in noradrena-
line (NA) neurotransmission are a contributor to the
process of nicotine dependence [3-5], smoking mainte-
nance [6], relapse [7], and withdrawal [3].
The neurobiology of addiction to multiple different
drugs has been explained primarily through the mechan-
isms underlying the reinforcing and rewarding proper-
ties of the specific addictive substances. The relationship
between the noradrenergic system and rewards mechan-
isms have been reported by a number of authors who
have pointed out that the major noradrenergic nucleus,
the locus ceruleus, sends its projections to ventral * Correspondence: peter.silverstone@ualberta.ca
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these reward and reinforcing pathways [8-10]. Moreover,
the release of dopamine in the nucleus accumbens
induced by all addictive substances is considered to be a
common mechanism in the development and mainte-
nance of the addiction; however, it has also been found
that the firing of midbrain dopamine cells is modulated
by noradrenergic neurons from the locus ceruleus [11].
This discovery, along with other research, led Wein-
shenker and Schroeder to propose the role of noradre-
naline pathways in stimulant additions [12].
Although the exact role of noradrenaline in nicotine
dependence is still uncertain, it has been demonstrated
that drugs which are efficacious at inhibiting NA reup-
take are also frequently clinically effective in treating
nicotine dependence, and are recognized as first line
agents in treatment [13,14]. Nonetheless, the efficacy of
current pharmaceutical aids remains wanting, and there
is currently a great need for other agents.
Towards this goal it has been suggested that another
noradrenaline reuptake inhibitor, atomoxetine, which is
used in the treatment of attention deficit disorder [15],
m a ya l s ob eu s e f u l[ 1 6 ] .A t o m o x e t i n e ’s clinical benefits
are believed to be due to noradrenergic augmentation in
the prefrontal cortex [17-19]. Atomoxetine also pos-
sesses a low affinity for multiple other neurotransmitters
including serotonin, dopamine, choline, g-aminobutyric
acid (GABA), adenosine transporters, and ion channels
[15,20-22]. Thus, actions of atomoxetine that increase
levels of other neurotransmitters may also have an indir-
ect effect mediated via increased noradrenaline release
[23,24]. It is therefore conceivable that mechanism of
action could have potential additional benefits in the
treatment of nicotine addiction. Furthermore, its inabil-
ity to raise the concentration of dopamine in the pre-
frontal cortex is probably linked to its low abuse
potential, a finding that has been supported in clinical
trials [15,23-25].
There have been three previous studies to date which
have examined the possible effectiveness of atomoxetine
for smoking cessation, all in patients who have a psychia-
tric diagnosis in addition to nicotine addiction, one in
non-psychiatric patients over 7 days, one in patients with
attention deficit hyperactivity disorder (ADHD), and one
in patients with schizophrenia [16,26,27]. All give tenta-
tive support to the possibility that atomoxetine can
reduce consumption and/or smoking behaviors. How-
ever, to date there have been no studies examining the
possible efficacy of atomoxetine in smoking cessation in
adult individuals who only have a nicotine addition over
more than 7 days. Given the need for additional treat-
ments the present study was designed to determine if
such a treatment warrants further investigation.
Methods
The objectives of the study were to determine if more
subjects in the atomoxetine treatment group had less
severe withdrawal symptoms, and smoked fewer cigar-
ettes, during a 21-day study period than those who
received placebo. The study was approved by the Health
Ethics Committee of the University of Alberta.
The length of time that subjects were studied (21 days)
was based upon findings showing that most individuals
who try and stop smoking relapse during this period [28].
While it is clear that larger phase III smoking cessation
studies have examined patients for 12 weeks for drugs
such as varenicline [29-31], other pilot studies of poten-
tial treatments have suggested a window of 3 to 4 weeks
is sufficient at the early stages of development [32].
Study population
The study population was defined as healthy volunteers
who wanted to quit smoking and met the Diagnostic
and Statistical Manual of Mental Disorders,f o u r t he d i -
tion (DSM-IV) criteria for nicotine dependence. They
were screened to ensure they met inclusion criteria and
did not have any criteria for exclusion (see below).
Inclusion criteria
The following inclusion criteria were used in the study:
(1) patients who want to quit smoking and who signed
an informed consent form approved by the ethics com-
mittee; (2) diagnosis of nicotine dependence according
to DSM-IV criteria [33]; (3) patients must be smoking
between 10 to 25 cigarettes per day, and have done so
for at least the previous 12 months (while the choice of
t h ed e g r e eo fn i c o t i n ed e p e n d e n c ei nt h i ss t u d yw a s
somewhat arbitrary, this is consistent with the average
number of cigarettes smoked per day in Canada cur-
rently being approximately 13; this is also consistent
with most smokers being in the ‘light’ range, since the
US National Institute on Drug Abuse classifies smoking
levels as light (less than 15 cigarettes per day), moderate
(15 to 24 cigarettes per day) and heavy (25 and more
cigarettes per day)); (4) age between 21 to 60 years old
(this age range was chosen since Canadian statistical
data for last decade showed that the majority of current
smokers belonged to the age groups that fall between 20
and 55 years of age [34]). Note that individuals aged
between 18 to 21 were specifically excluded, as we were
concerned that they may not have an established smok-
ing pattern and therefore withdrawal symptoms may be
less likely to have manifested.
Exclusion criteria
The following exclusion criteria were used in the study:
(1) any current Axis I or Axis II psychiatric disorder
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psychiatric conditions in the study group so as to avoid
potential issues with applicability of the study: to ensure
this a semistandardized interview, the Mini International
Neuropsychiatric Interview (MINI) compatible with
DSM-IV diagnostic criteria [35] was performed on all
potential subjects); (2) history of intolerability, hypersen-
sitivity or allergy to atomoxetine, or use of atomoxetine
within 30 days of screening; (3) presence of disorders
that could conceivable be exacerbated by atomoxetine
(specifically, narrow angle closure glaucoma, urinary
outflow obstruction, hypertension, and neurological dis-
orders, particularly tics and Tourette’s syndrome, or a
history of epilepsy or seizures); (4) use of concomitant
medication that could potentially interact with atomoxe-
tine including monoamine oxidase inhibitors (MAOI),
antihypertensive medication, or any concomitant medi-
cation that was a cytochrome 2D6 inhibitor (CYP2D6),
since atomoxetine’s elimination involves the CYP2D6
system; (5) use of any recreational or illegal drugs in the
3 months prior to the study, of individuals who met cri-
teria for alcohol dependence or alcohol abuse in the 3
months prior to the study; (6) presence of any suicidal
ideations during screening testing.
Screening and baseline
To ensure that patients met inclusion criteria the fol-
lowing baseline information was collected and a physical
examination was also completed: demographic data:
gender, age, educational level, income, and occupation,
marital status, and ethnicity; smoking history and deter-
mine that the individuals met diagnostic criteria for
nicotine dependence according to DSM-IV classification;
psychiatric history including other substance use/abuse;
the Mini International Neuropsychiatric Interview; med-
ical history; and concomitant medications.
Outcome measurements
The following five outcome measurements were
employed to determine baseline ratings for subjects, and
how they subsequently changed: (1) severity of nicotine
dependence utilizing the Cigarette Dependence Scale
(CDS) [36,37]; (2) withdrawal symptoms utilizing the
Cigarette Withdrawal Scale (CWS) [38,39]; (3) smoking
urges and craving utilizing the Questionnaire for Smok-
ing Urges (QSU) [40-42]; (4) Self-monitoring diary of
smoking, which was completed daily by subjects (this
reflected the subject’s assessment of how much they
were smoking daily); (5) salivary cotinine measurements,
as recommended in previous studies [43-46]. Cotinine is
the major metabolite of nicotine and accounts for
approximately 75% of all byproducts of nicotine metabo-
lism [47,48]. Cotinine can be detected in diverse body
fluids such as urine, serum [49], cervical mucus [50],
semen [51], saliva [52-54], and amniotic fluid [55].
In addition to the outcome measurements participants
underwent a repeat physical examination that included
measurement of vital signs (blood pressure, pulse, tem-
perature) and weight.
Both treatment and placebo groups received the fol-
lowing advice and information about stopping smoking,
and these were repeated at each visit: (1) advised to dis-
cuss quitting attempt with family members; (2) to antici-
pate challenges during quitting attempt; (3) likely
withdrawal symptoms, and triggers for these; (4) to
remove tobacco products from their home; (5) if there
were others in their home who smoked, to try and get
them to also stop; (6) to ask other smokers in the same
household not to smoke in their presence and/or only
smoke outside of the house; (7) to stop alcohol use
(exclusion criteria in our research and trigger); (8) dis-
cussed health risks and rewards that quitting provides;
(9) provided with information about programs and
resources for smokers within the city.
Randomization and details of measurements at each visit
In order to avoid selection bias, the assignment of sub-
jects to the two study groups was randomized by a com-
puter-generated code and this study was carried out in a
double-blind manner. Participants were randomized and
assigned to either atomoxetine or placebo-treatment arm
during the baseline visit. Coding of study subjects (study
subject number) was performed by assigning a unique
alphanumeric sequential code to each participant.
After signing an informed consent form, the subjects
underwent a screening interview that included a screen-
ing questionnaire consisting of demographic data, smok-
ing history, medical history, psychiatric history, and
social history of the patient, a screening questionnaire
with study inclusion and exclusion criteria, the struc-
tured clinical interview for Diagnostic and Statistical
Manual (DSM-IV) to confirm that the subject met
appropriate diagnostic criteria of DSM-IV for nicotine
dependence, and the MINI to exclude other psychiatric
disorders.
After completion of the interview subjects had a phy-
sical examination that included the following measure-
ments: weight (kg), blood pressure (mmHg), pulse
(bpm) and temperature.
Subjects also underwent a cotinine saliva test to deter-
mine their smoking status and baseline levels. Those
volunteers, whose screening interview and cotinine sal-
iva test showed that they were eligible for trial participa-
tion, were entered into the study.
The baseline visit occurred within 7 days of the
screening visit. Complete information about smoking
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chiatric, and social history of each participant were col-
lected during this visit. This was to complete any
missing information from the screening visit. To ensure
the greatest level of accuracy for the outcome measure-
ments in our study we combined self-reported question-
naires and a self-monitoring diary with objective
measurement of a biological marker for smoking,
namely the cotinine saliva test, which was carried out at
every visit as were all the outcome measurements.
At the baseline visit (day 1, week 0) participants
underwent randomization and were assigned to either
atomoxetine or placebo-treated group. Both at baseline,
and each subsequent visit, the study drug was dispensed
as a 7 ± 2 day supply, with a total of nine capsules in
each container to allow for delayed visits.
Subjects were instructed to return for follow-up after a
1-week period (± 2 days) and bring the container and
the rest of the pills (if any). Participants were also
instructed about the administered daily dose of the ato-
moxetine, with each subject receiving 40 mg once a day.
All subjects were provided with information and bro-
chures about support services and self-help groups for
individuals who are in the process of quitting smoking.
Subjects were also instructed that follow up visit will
be held every 7 days (± 2 days) during the 21-day treat-
ment period. Thus, each subject had three additional
follow-up visits (day 7, week 1; day 14, week 2; day 21,
week 3). Participants were advised to report all side
effects to study medication and reminded that they were
free to drop out of the study at any time if they wished.
Participants underwent a repeat physical examination
that included measurement of vital signs (blood pres-
sure, pulse, temperature) and weight. At each visit the
cotinine test on a salivary sample was repeated to moni-
tor compliance and to verify self-reporting of smoking.
It should be noted that the test used (NicAlert) is not a
linear scale as a score of 1 represents 1 to 10 ng/ml
while a score of 5 represents 500 to 2,000 ng/ml. This is
therefore an indication, not a direct measurement, of
serum cotinine levels. Therefore, statistical comparisons
of changes with this test are only useful to give an indi-
cation of a reduction (or lack of this), rather than give
definitive changes in serum cotinine levels.
At each visit adverse events were collected as was the
self-monitoring diary, and a new one was provided for
the next week. Participants were instructed to fill out
the diary every day and return it during the next fol-
low-up visit. Compliance with medication was also cal-
culated. In situations where pills were returned or
treatment interruption occurred, volunteers were inter-
viewed and the reasons such as relapse or adverse event
were recorded. Concomitant medications were also
recorded.
Statistical analysis
I nt h i ss t u d yw eu s e datt e s tt oc o m p a r et h er e s u l t s
between the group, using both the completer data and
the results on a last observation carried forward (LOCF)
basis to compare the mean scores for each group at
each visit. Results were considered statistically signifi-
cant at the P < 0.05 level.
We utilized a two-sample t test to compare results
between the groups at each time point. This was per-
formed both for the group of individuals who completed
each visit (’treatment group’)a sw e l la sf o rt h o s ew h o
stopped the study early and whose missing data was
completed using an LOCF analysis (’LOCF treatment’).
These are shown for each of the five key outcome
measures, the CDS, CWS, QSU, the number of cigarettes
smoked per week (NCSW), and cotinine salivary levels.
Sample size calculation
In order to determine the differences between treatment
and placebo groups, the sample size was calculated by a
power analysis. This was based on the reduction in self-
reported smoking urges as measured by the QSU in a
previous study of the effects of atomoxetine in smoking
cessation [16]. In this study the baseline QSU score was
72 with a standard deviation of 19, while following treat-
ment with atomoxetine it was 82 with a standard devia-
tion of 17. Assuming that the study should be powered
sufficiently to detect a similar change in magnitude, a
sample size calculation was made using these values and
an a error level of 5% (corresponding to a 95% confi-
dence interval) and a b error level of 10% (the probabil-
ity of incorrectly failing to reject the null hypothesis that
there is no difference in the average values). Using this
information the number of subjects required to reach
statistical significance was calculated as 56. To account
for dropouts, a total of 60 subjects in each arm were felt
to be required. Thus, it was the intention to recruit a
total of 120 subjects, 60 in each arm.
Results
Recruitment and demography
A total of 34 potential subjects attended for a screening
visit. However, 14 did not meet inclusion and exclusion
criteria. Thus, a total of 20 people entered the study. Of
these 20, 3 individuals attended the baseline visit, but
did not take any study medication and were therefore
not included in the study. The study population, there-
fore, consists of 17 subjects who were randomized to
receive double-blind medication. Of these, a total of five
dropped out during the study, all due to side effects. In
all, 12 subjects completed the study.
The demographic characteristics of the study partici-
pants are summarized in Table 1. There were no statis-
tically significant differences between the groups.
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There were no statistically significant differences between
clinical characteristics and the family history of partici-
pants in both treatment groups. Thus, there were no sta-
tistically significant differences between the two groups
in terms of history of mental disorders; comorbid general
medical conditions; health concerns/problems related to
smoking; alcohol use or abuse; use of medications for the
treatment of medical conditions throughout the study;
family history of mental health conditions other than
nicotine dependence; or family history of smoking.
Smoking-related history for all participants
All 17 participants met criteria for nicotine dependence
according to DSM-IV classification. In terms of speci-
fics, all of them had nicotine dependence with physiolo-
gical dependence. A summary of their current and past
smoking behavior is shown in Table 2.
Among all study participants, only one individual in
the atomoxetine group and three individuals in the pla-
cebo group reported the development of respiratory
problems related to smoking. One individual in the pla-
cebo group was diagnosed with chronic obstructive pul-
monary disease (COPD).
There were no statistically significant differences
between the two treatment groups (Fisher’se x a c tt e s t
and non-parametric Mann-Whitney tests).
CDS scores
The changes over time for the CDS scale are shown in
Figure 1. The results showed that there was a statisti-
cally significant difference between the atomoxetine
treatment arm compared to those in the placebo group
at the end of the study (mean score of 26.8 vs 42.3
respectively, P < 0.05). However, this difference was not
statistically significant in an LOCF analysis.
CWS scores
The changes over time for the CWS scale are shown in
Figure 2. In the placebo group there was an increase in
the severity of withdrawal symptoms of 4.5 during the
study period, with a peak increase of 8.2 at week 2. In
Table 1 Demographic characteristics of study participants
Characteristics Atomoxetine
group
(N = 9; 52.9%)
Placebo
group
(N = 8; 47.1%)
P value
Age, years:
Mean (SD) 40.9 (11.9) 43 (9.9) 0.699
a
Range 25 to 57 31 to 58
Gender, n (%):
Male 5 (55.6%) 3 (37.5%) 0.637
b
Female 4 (44.5%) 5 (62.5%)
Ethnicity, n (%):
White 8 (88.9%) 7 (87.5%) 1.000
Other
c 1(11.1%) 1 (12.5%)
Education, n (%):
High school 2 (22.2%) 0 (0%) 0.471
College/university 7 (77.8%) 8 (100%)
Occupation, n (%):
Student/unemployed 3 (33.3%) 1 (12.5%) 0.576
Employed 6 (66.7%) 7 (87.5%)
Income, n (%):
Low/moderate 7 (77.8) 7 (87.5%) 1.000
High 2 (22.2%) 1 (12.5%)
Marital status, n (%):
Married/common law 5 (55.6%) 1 (12.5%) 0.131
Single/divorced 4 (44.5%) 7 (87.5%)
aThe t test was used to compare the means ages of both groups.
bThe Fisher’s exact test for used to compare the proportions.
cThe other subgroup incorporates the following ethnicities: one Asian in the
atomoxetine group and one Métis individual in the placebo group.
Table 2 Smoking data for all study participants
Characteristics Atomoxetine
arm (N = 9)
Placebo
arm
(N = 8)
P value
Length of every day smoking, years:
Mean (SD) 20.9 (11.3) 23.1 (8.4) 0.655
Range 5 to 40 11 to 36
Number of cigarettes per day, n (%):
Mean (SD) 19.1 (5.5) 19.1 (5.0) 0.979
Range 11 to 27.5 12 to 27
Age of smoking initiation, years: 0.984
Mean (SD) 16.3 (2.8) 16.4 (5.8)
Range 13 to 21 11 to 29
Number of quitting attempts:
Mean (SD) 4.7 (3.2) 5.9 (5.8) 0.596
Range 2 to 10 2 to 20
Median length of the recent
attempt to quit smoking, days:
Median 3 13 0.409
Range 2 to 3,600 3 to 180
Percentile 25 2 7
Percentile 50 3 13.8
Percentile 75 510 120
Median of average length of
quitting attempts, days:
Median 60 19.3 0.630
Range 2 to 7,200 1 to 360
Percentile 25 2.25 11.4
Percentile 50 60 19.3
Percentile 75 2,205 78
Previous use of smoking cessation
medications, n (%):
8 (88.9%) 7 (87.5%) 1.000
Help of smoking cessation
medication, n (%):
6 (66.7%)
a 7( 8 7 . 5 % )
a 0.467
aOne smoker from atomoxetine treatment group and one smoker from
placebo group did not use any medication for smoking cessation.
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of 2.0 during the study, and at week 2 the peak increase
was only 0.4. These differences were statistically signifi-
cant (P < 0.05) in the completer group. However, when
the LOCF measurements were made, the differences
between the groups were no longer statistically signifi-
cant. These results suggest that those study participants
who completed the study and received atomoxetine may
have experience a reduction in their nicotine withdrawal
symptoms compared to those who received placebo, but
the data is by no means clear in this regard.
QSU score
The changes over time for the QSU scale are shown in
Figure 3. It can be seen that at week 2 there is a reduc-
tion in the QSU scores in the treatment group (from a
baseline measurement of 377 to 134), and this was
accompanied by a statistically significant difference
between the atomoxetine treatment arm and placebo
treatment arm at week 2 (P = 0.049). However, the dif-
ference narrowed at week 3 and just failed to reach sta-
tistical significance at the final visit (P = 0.058). Overall,
the QSU scores did not change in the placebo group,
while there was a marked reduction in those individuals
received atomoxetine and who completed the study.
In contrast, there were no statistically significant dif-
ferences between the placebo group and the LOCF
treatment group at any time point, and at week 1 the
LOCF groups scores were in fact higher, although this
was not statistically significant (P = 0.115).
Number of cigarettes smoked per day
Changes in the self-reported number of cigarettes
smoked are shown in Figure 4. The mean number of
cigarettes smoked per day by patients before they
started was 16.3 in the placebo group and 16.4 in the
treatment group. This decreased considerably in both
groups during the first week, but whereas it started to
increase back up towards baseline in the placebo group,
it continued to decrease in the treatment group. This
data would be consistent with individuals on placebo
decreasing their smoking during the first week of their
participation, but their smoking rates then increased
back to 7.4 per day as the study progressed. In contrast,
Figure 1 Mean scores on the Cigarette Dependence Scale
(CDS). The figure shows the changes in the mean scores on the
CDS over the 3-week study period in the group receiving placebo
(placebo group), those receiving atomoxetine who completed the
study (atomoxetine group), and those who received atomoxetine
but dropped out during the study (last observation carried forward
(LOCF) atomoxetine group). A two-sample t test demonstrated
statistically significant difference (P < 0.05) between the mean
scores in the atomoxetine group compared to the placebo groups
at 3 weeks (*).
Figure 2 Mean scores on the Cigarette Withdrawal Scale (CWS).
The figure shows the changes in the mean scores on the CWS over
the 3-week study period in the group receiving placebo (placebo
group), those receiving atomoxetine who completed the study
(atomoxetine group), and those who received atomoxetine but
dropped out during the study (last observation carried forward
(LOCF) atomoxetine group). A two-sample t test demonstrated
statistically significant difference (P < 0.05) between the
atomoxetine group and placebo groups at 3 weeks (*).
Figure 3 Mean scores on the Questionnaire of Smoking Urges
(QSU) scale. The figure shows the changes in the mean scores on
the QSU over the 3-week study period in the group receiving
placebo (placebo group), those receiving atomoxetine who
completed the study (atomoxetine group), and those who received
atomoxetine but dropped out during the study (last observation
carried forward (LOCF) atomoxetine group). A two-sample t test
demonstrated statistically significant difference (P < 0.05) between
the atomoxetine group and placebo groups at 2 weeks (*), but this
just failed to reach statistical significance at 3 weeks.
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the number of cigarettes smoked daily continued to
decrease throughout the study with them mean number
of cigarettes smoked in the treatment group being 1.8 at
the end of the study, as reported in their daily diaries.
This difference at the end of the study was statistically
significant (P = 0.015). Nonetheless, when the last obser-
vation carried forward (LOCF) analysis was considered,
there were no statistically significant differences between
the atomoxetine group and the placebo group.
It is also important to note that none of the partici-
pants stopped smoking completely.
Salivary cotinine
When comparing the mean levels of salivary cotinine in
the two groups at week 3 there was a trend towards a
statistically significant difference between those who had
taken atomoxetine throughout the study and the pla-
cebo group with a mean decrease in scores from 4.1 to
2.8 compared to 4.5 to 3.8 (P = 0.069). However, it
should be noted that the reduction from 4.1 to 2.8 in
the treatment group in fact represents a significant
decrease in cotinine levels from a level of approximately
200 ng/ml (represented by a score of 4 with this test) to
approximately 80 ng/ml (represented by a score of 2.8).
Thus, the direction of changes is consistent with the
reported reduction in the number of cigarettes smoked
in the atomoxetine treated group compared to the pla-
cebo group. Nonetheless, it should be noted that when
using LOCF there were no statistically significant differ-
ences between the atomoxetine treatment group and the
placebo group.
Other measurements
There was a statistically significant increase in both sys-
tolic and diastolic blood pressure in the atomoxetine
group compared to the placebo group (Table 3). There
were no statistically significant differences between the
groups for heart rate, respiratory rate, temperature, or
body weight (Table 3).
Analysis showed that individuals who dropped out from
the study were not significantly different from those who
completed the study in terms of comorbid general medical
conditions (P = 0.728), use of medications for the regular
treatment of medical problems (P = 0.169), use of alcohol
(P = 0.536), use of other addictive substances (P = 0.536),
or in terms of history of mental health disorders, either
personal (P = 0.362) or family (P = 0.610).
Adverse events reported by participants in the study
Several participants discontinued their participation dur-
ing the study due to adverse events (Table 4). When the
data was analyzed it became apparent that all disconti-
nuations occurred in those receiving atomoxetine, due
to side effects experienced by individuals. Three partici-
pants dropped out during the first week of taking the
drug, one individual dropped out during the second
week, and one more participant discontinued his partici-
pation during the third week of the study. Thus, more
than 50% of those started on atomoxetine were not able
Figure 4 Mean number of cigarettes smoked in period between
visits. The figure shows the changes in the mean number of
cigarettes smoked each day at baseline, and then during the 6 days
between each visit. These are shown for the group receiving placebo
(placebo group), those receiving atomoxetine who completed the
study (atomoxetine group), and those who received atomoxetine but
dropped out during the study (last observation carried forward
(LOCF) atomoxetine group). It can be seen that there was a marked
drop in all groups. A two-sample t test demonstrated statistically
significant difference (P < 0.05) between the atomoxetine group and
placebo groups during this last measurement period (*).
Table 3 Changes for study participants during the study
Characteristics Atomoxetine
arm (N = 9)
Placebo
arm (N = 8)
P value
(if significant)
Systolic blood pressure,
mmHg:
Baseline 116.4 107.5
At end of study (LOCF) 120.6 102.8 0.007
Diastolic blood pressure,
mmHg:
Baseline 72.8 68.1
At end of study (LOCF) 76.7 68.9 0.009
Heart rate, beats/min:
Baseline 66.8 70.0
At end of study (LOCF) 69.6 72.1
Respiratory rate, breaths/
min:
Baseline 14.7 14.8
At end of study (LOCF) 16.2 15.3
Body temperature
smoking, °C:
Baseline 36.4 36.1
At end of study (LOCF) 36.5 36.3
Mean weight, kg:
Baseline 80.9 67.9
At end of study (LOCF) 81.4 68.5
LOCF = last observation carried forward.
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Page 7 of 11to tolerate it at the dose used, which is the recom-
mended starting dose for adults who have ADHD.
In total there were 65 adverse events reported,
although none of them were serious adverse events. The
most frequent adverse event was insomnia, followed by
dizziness, fatigue, nausea, decreased concentration, and
headache.
Discussion
This study was a randomized, placebo group of the pos-
sible use of atomoxetine to help nicotine addiction,
something that represents a major health problem to
many societies. It is also the first study to examine the
possible efficacy of atomoxetine in adults with no other
psychiatric diagnoses for up to 3 weeks.
Despite the significant limitations outlined, the results
were of interest, being the first double-blind, placebo-
controlled, study to examine the effects on atomoxetine
in individuals who only have a diagnosis of nicotine
addiction. Furthermore, there were several indications
that in those individuals who could tolerate the side
effects of atomoxetine, there may be clinically relevant
benefits compared to placebo.
Thus, in those subjects who stayed on atomoxetine for
21 days there were several benefits that, taken together,
may suggest this drug is potentially effective. Thus,
these individuals had a reduction on the CDS (from a
mean of 54 to 27); had a reduction on the CWS (2.0)
compared to an increase in the placebo group (5.5); had
a marked reduction on the QSU (from 368 to 134)
while the placebo group had a very minor reduction
(from 276 to 272); had a marked reduction in the num-
ber of cigarettes smoked during the study (from 43 to
11) while the numbers smoked in the placebo group
increased; consistent with this large drop in the reported
number of cigarettes smoked the atomoxetine group had
a reduction in cotinine levels of 1.3 while the placebo
group had a decrease of only 0.7.
There have been three previous studies to date that
have examined the possible effectiveness of atomoxetine
for smoking cessation, all in patients who have other
psychiatric diagnoses. Thus, in a 2-day blinded crossover
study in 15 adults with ADHD who smoke, it was found
that their usual ADHD medication reduced withdrawal
symptoms overnight [26], and of this group 4 patients
were on atomoxetine (25 to 40 mg/day). In a 7-day dou-
ble-blind crossover study in 50 individuals without a
psychiatric disorder it was found that atomoxetine treat-
ment (25 mg/day for 2 days then 40 mg/day for 2 days
then 1.2 mg/kg) led to a reduction in subjective withdra-
wal symptoms and in smoking urges among smokers
treated with atomoxetine compared to placebo [16]. In a
small double-blind study in patients with schizophrenia
who smoked, either placebo (n = 5), or atomoxetine at
40 mg/day (n = 4), or atomoxetine at 80 mg/day (n = 3)
were administered for 14 days [27]. In these patients no
statistically significant changes in smoking behaviors, as
measured by smoking consumption or carbon monoxide
(CO) levels were observed, although a 22% decrease in
number of cigarettes per day and a 35% decrease in CO
levels between baseline and day 8 in subjects taking the
80 mg/day dose were noted.
The findings from the present study are consistent
with these initial findings. However, there were signifi-
cant methodological differences between the studies,
particularly when comparing to the most similar study,
that by Ray and colleagues [16]. This latter study used
the Fagerstrom Test for Nicotine Dependence as their
primary outcome measure, and additionally a different
measure of withdrawal was also used, the withdrawal
symptom checklist (WSC) [16]. Another major metho-
dological difference was that in the current study
Table 4 Adverse events recorded during the study
among participants
Adverse events Total Atomoxetine
(n = 9)
Placebo
(n = 8)
Insomnia 7 5 (55.6%) 2 (25.0%)
Anxiety/nervousness 2 3 (33.3%) 0 (0%)
Dry mouth 3 3 (33.3%) 0 (0%)
Dizziness 5 2 (22.2%) 3 (37.5%)
Fatigue 4 2 (22.2%) 2 (25.0%)
Nausea 4 2 (22.2%) 2 (25.0%)
Decreased concentration 4 2 (22.2%) 2 (25.0%)
Headache 4 2 (22.2%) 2 (25.0%)
Diaphoresis 3 2 (22.2%) 1 (12.5%)
Urinary retention 2 2 (22.2%) 0 (0%)
Increased energy, feeling ‘high’ 2 2 (22.2%) 0 (0%)
Paresthesia (tingling sensation) 2 2 (22.2%) 0 (0%)
Restless 2 2 (22.2%) 0 (0%)
Irritability 2 2 (22.2%) 0 (0%)
Sadness/low mood 2 1 (11.1%) 1 (12.5%)
Common cold 2 1 (11.1%) 1 (12.5%)
Diarrhea 1 1 (11.1%) 0 (0%)
Constipation 1 1 (11.1%) 0 (0%)
Sexual dysfunction 1 1 (11.1%) 0 (0%)
Chills 1 1 (11.1%) 0 (0%)
Tense 1 1 (11.1%) 0 (0%)
Feeling that time goes fast/speedy 1 1 (11.1%) 0 (0%)
Decreased appetite 1 1 (11.1%) 0 (0%)
Recklessness 1 1 (11.1%) 0 (0%)
Stomach pain 1 1 (11.1%) 0 (0%)
Fall 2 0 (0%) 2 (25.0%)
Sinusitis 1 0 (0%) 1 (12.5%)
Bladder infection 1 0 (0%) 1 (12.5%)
Heart palpitation 1 0 (0%) 1 (12.5%)
Other (assault, car accident) 4 2 (22.2%) 0 (0%)
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Page 8 of 11participants were asked to stop smoking at baseline, and
then their withdrawal symptoms and smoking urges
were monitored over the following 3 weeks. In contrast,
Ray and colleagues did not ask the subjects to stop
smoking, but observed changes in withdrawal symptoms
while allowing them to continue to smoke [16]. This
approach may, in part, explain the differences in the
QSU score. Further differences were that in the present
study a ten-item version of QSU scale was used, based
upon an analysis carried out by Toll and colleagues [41].
Also, after obtaining permission from the originator of
the scale, Dr. Tiffany, we received his original scoring
version that was based on a 0 to 100 rating scale. In
contrast, Ray and colleagues examined the QSU using a
32-item scale with response scale ratings from 1 to 7.
The problems with this approach were illustrated by
Toll and colleagues, who concluded that there was no
consistency in term of the scoring and type of this ques-
tionnaire [36]. These differences illustrate the difficulty
of directly comparing results across studies that have
such different methodologies. They also illustrate the
need for a more standardized approach to measuring
the effectiveness, or otherwise, of atomoxetine on smok-
ing behaviors.
In terms of adverse events, several large studies
[56-62] have reported the following as the most com-
monly reported adverse events associated with the use
of atomoxetine in adults as: dry mouth (16% to 55%),
decreased appetite (12% to 50%), insomnia (17% to
35%), nervousness (35%), constipation (7% to 20%), erec-
tile dysfunction (5% to 11%), nausea (12% to 40%), dizzi-
ness (6% to 15%), decreased libido (7%), sweating (5% to
20%), fatigue (16% to 25%), increased heart rate (17%),
hypertension (10%), hot flashes (10%), depression (10%),
and urinary problems (6 to 10%). The adverse events
experienced by participants in the current study are
compatible with these findings.
Nevertheless, the study still has several limitations and
potential biases that will need to be discussed when the
results are considered.
First of all, the number of participants was small,
although appropriate for a pilot study. Nonetheless, the
small size of the sample makes it difficult to generalize
the results more widely. The sample size analysis indi-
cated that up to 120 individuals were required for a
fully powered study.
The second major limitation of the study is linked to
this first point, and that is that the statistical findings
were far from robust. Because of the small numbers it is
difficult to be confident that even where statistically sig-
nificant findings were found that they have clinical rele-
vance. Furthermore, there were different findings when
completers only were considered as opposed to the last
observation carried forward analysis. This finding
emphasizes that the results are preliminary, and should
be taken as possibly indication of utility only. They
should not be taken as support for using this drug in
individuals until more robust data is available.
A third limitation was the large dropout rate among
the atomoxetine treatment group. The recommended
starting dose for atomoxetine in adults with ADHD is
40 mg. This was the dose used in the present study.
However, less than 50% of those who started on this
dose were able to tolerate it for 3 weeks. If this study
was to be repeated it would be strongly recommended
that a lower dose was used, possibly with a slow dose
titration over 1 or 2 weeks. The large number of side
effects experienced by those who took part in the study
is a testament to how significantly otherwise healthy
individuals were affected. Of interest is the fact that this
dose is recommended for all teens and adults over 70
kg, but the mean starting weight of the subjects in the
atomoxetine group was 81 kg. The small number of
subjects who started the study, and the even smaller
number of those treated with atomoxetine who com-
pleted it (n = 4), affected the statistical power of the
study and made the results far less reliable. Also, none
of the study subjects was able to remain completely
abstinent for the 21-day period, so even for those that
could tolerate this drug, the success was not as benefi-
cial as might be desired. The limited sample also pre-
vented us from generalization and extrapolation of
acquired results. Thus, our findings should be inter-
preted cautiously.
Fourthly, the duration of the study was 21 days, dur-
ing which the effects of atomoxetine on nicotine with-
drawal were examined. The duration of the study may
not have been long enough to assess the effect of ato-
moxetine on nicotine withdrawal, especially, taking into
account that the first 3 to 4 weeks of abstinence are
considered to be an acute nicotine withdrawal period
that represents the high-risk period for relapse [28]. Ide-
ally, longer study periods would show the utility (or
otherwise) of atomoxetine in achieving and maintaining
abstinence. Thus, in future studies, a longer duration of
atomoxetine administration may be required to deter-
mine any differences between the natural progression of
nicotine withdrawal and the time required to observe
the therapeutic effect of atomoxetine. Therefore, it
should be appreciated that the length of treatment in
the present study was experimental and was not suffi-
cient enough to determine a definitive therapeutic effect
of atomoxetine on smoking cessation.
L a s t l y ,b e c a u s et h eg r o u p sw e r es m a l lt h e r ew e r ed i f -
ferences between them that could have affected the
results. Thus, the atomoxetine and placebo group dif-
fered (even if not statistically significantly) in terms of
gender, education, occupation, income, marital status,
Silverstone and Dadashova Annals of General Psychiatry 2012, 11:6
http://www.annals-general-psychiatry.com/content/11/1/6
Page 9 of 11history of mental disorder, number with health concerns
from smoking, use of medication for medical conditions,
length they had been smoking, median length of
attempts to quit smoking, median length of previous
attempts to stop smoking, and helpfulness of previous
medication for smoking cessation. While these differ-
ences may not have been statistically significant on an
individual basis, in small groups of subjects such differ-
ences can conceivably have a significant cumulative
effect that could impact the results. Consideration of the
discussion of the results that follows should take all
these study limitations into account.
Conclusions
In conclusion, the data from the present study support
s u g g e s t i o n st h a tt h e r em a yb es o m eu s e f u lr o l ef o ra t o -
moxetine in the treatment of smoking cessation, parti-
cularly as the number of cigarettes per day decreased,
and this was supported by a decrease in the serum coti-
nine levels. However, the size of the study and the lim-
itations identified, mean that further work is required to
determine this more definitively. One matter that will
need to be address in future studies will involve both
the dose used and the length of treatment.
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